Background
Endogenous nitric oxide (NO) is responsible for the regulation of vascular tone. 1 The enzyme, NO synthase, generates NO from L-arginine. NO then activates guanyl cyclase and increases the production of cyclic guanosine monophosphate (cGMP). This in turn activates a cascade of GMP-dependant protein kinases resulting in an efflux of calcium from cells and in the relaxation of the vascular smooth muscle. In addition to the potent effect on vascular muscle tone, NO is critical in many physiological processes and in the development of multiple organ systems. Endogenously released NO may influence many facets of perinatal lung development, including the development of the lung parenchyma, bronchi and vascular structures. 2 NO also contributes to the growth of the lung parenchyma and to extracellular matrix deposition, and may modulate surfactant production and inflammation in the developing lung. 2 These findings point to a wide variety of roles that could be played by NO in the treatment of term and preterm infants.
The following review will summarize the findings from the systematic overviews regarding inhaled nitric oxide (iNO) use in term and preterm infants authored by Finer and Barrington in the Cochrane Library. 3, 4 Inhaled nitric oxide in term and late preterm infants In term and late preterm infants, persistent pulmonary hypertension of the newborn (PPHN) is a frequent cause of hypoxemic respiratory failure, affecting 0.43 to 6.8 per 1000 live births. 5 PPHN can be considered as a primary condition owing to difficulties in neonatal adaptation, or as a secondary complication of diseases such as respiratory distress syndrome, meconium aspiration syndrome, sepsis or congenital lung malformations such as diaphragmatic hernia. Current therapy for PPHN includes mechanical ventilation (with the possibility of hyperventilation), muscle paralysis/relaxation, sedation and alkalosis (either through hyperventilation or through the administration of sodium bicarbonate). 5 No trials have proven that any of these interventions can reduce mortality in infants with PPHN. Only extracorporeal membrane oxygenation has proven to be useful in this condition; 6 however, extracorporeal membrane oxygenation (ECMO) is expensive, invasive and potentially quite risky.
In animal models, the inhibition of NO production can cause pulmonary and systemic hypertension. 7 In other animal models of PPHN, iNO has been shown to reduce pulmonary hypertension without affecting systemic vascular resistance. [8] [9] [10] These findings have led to clinical studies of iNO for respiratory failure in infants born near or at term.
Clinical trials of NO for respiratory failure in term or late preterm infants have been reviewed by Finer and Barrington.
3 For purposes of the review, Finer and Barrington selected randomized, controlled trials of late preterm (near term) or term newborn infants with hypoxemia suspected to be because of either lung disease, pulmonary hypertension or both. Owing to the unique issues associated with congenital diaphragmatic hernia (CDH), these infants were evaluated separately. Infants with shunting because of structural congenital heart disease were excluded from this analysis.
Fourteen trials were identified for the review. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Study enrollment varied in size from 14 infants 11 to 235 infants. diaphragmatic hernia. 11, 15, 16, 18, 20, 22, 24 In the analysis of these studies, Finer and Barrington analyzed infants with diaphragmatic hernia separately. All studies required the enrolled infants to have evidence of hypoxemic respiratory failure. The majority of the studies required echocardiographic evidence of PPHN. 12, 13, 15, 16, 18, 19, 22, 23 Inhaled nitric oxide was given in a 'masked' or 'unmasked' manner. In some of the studies, infants in the control group were allowed to be treated with iNO if they met predefined criteria for persistent respiratory failure. 11, 12, 13, 19, 20, 23, 24 This is a critical issue in the interpretation of these trials and in the meta-analysis. Although ethically responsible, the treatment of the control group with iNO makes interpretation of the data problematic. If iNO is successful at improving the clinical condition of the infant, less mortality may be seen in the control group that was allowed to receive iNO. However, if there are clinically important side effects of iNO, these will be confounded by this type of 'rescue' treatment.
The clinical effect of iNO treatment in term or late preterm infants is discussed below and summarized in Table 1 . The effect of iNO on short-term improvement of hypoxemic respiratory failure was reported in many studies. 11, 12, 14, 15, 18, 21 With the exception of Barefield et al., 11 all of these studies reported a significant improvement in the oxygenation index (OI) associated with iNO administration. Mortality was unchanged by the use of iNO. In the overall estimate from the nine trials that reported on mortality, no decrease in the risk of mortality was noted (typical relative risk (RR) 0.91, 95% CI 0.60, 1.37). No differences were noted when subgroup analyses were carried out separately for trials that used iNO in control subjects with worsening respiratory failure and in trials that did not allow the 'rescue' use of iNO. In the three studies that allowed for backup use of iNO, 11, 19, 20 there was also no statistically significant difference in the risk of mortality (typical RR 0.86, 95% CI 0.37, 1.98). In the six studies that did not allow for backup use of iNO, [14] [15] [16] 18, 21, 22 the typical RR of mortality was 0.92 (95% CI 0.58, 1.48). The number of infants placed on ECMO was noted to be decreased in the trials that did not allow for the backup use of iNO. [14] [15] [16] 18, 21, 22 In these trials, a significant reduction in the risk of being placed on ECMO was noted (typical RR 0.61, 95% CI 0.51, 0.72). In the two trials that allowed for the backup use of iNO and also reported on the use of ECMO, 11, 19 no reduction in the risk of requiring ECMO was noted (typical RR 1.14, 95% CI 0.64, 2.02). The overall estimate of effect from all studies shows a significant decrease in the requirement for ECMO (typical RR 0.63, 95% CI 0.54, 0.75). When evaluated as a combined outcome of death or requirement for ECMO, a significant decrease in the risk of dying or in the requirement of ECMO was noted in the trials that did not allow for the backup use of iNO (typical RR 0.65, 95% CI 0.55, 0.76). No such decrease in risk was noted in the trials that allowed for the backup use of iNO 11, 19, 20 (typical RR 1.15, 95% CI 0.67, 1.97). However, when all trials are evaluated, there was a significant decrease in the risk of death or in the requirement for ECMO (typical RR 0.68, 95% CI 0.59, 0.79). In technically developed countries, no infant at term or near term would be allowed to die of hypoxic respiratory failure without attempting to place the infant on ECMO, suggesting a significant advantage of iNO in these infants.
There is much less data regarding the neurodevelopmental outcome in these infants. Only two studies reported on neurodevelopmental disability at 18 to 24 months. 25, 26 Neither study showed a significant difference in infants regarding neurodevelopmental disability. The typical RR of developmental disability at 18 to 24 months was 0.97 (95% CI 0.66, 1.44).
Inhaled nitric oxide seems equally effective when instituted at a moderate or more severe threshold for hypoxemic respiratory failure. Two studies evaluated the effect of iNO when given immediately to infants with moderate respiratory disease severity compared with that as a later treatment when infants had more severe disease. 23, 24 These studies showed no reduction in the risk of death (typical RR 0.73, 95% CI 0.34, 1.54) or in the risk of death or requirement for ECMO (typical RR 0.85, 95% CI 0.54, 1.32).
Less data are available regarding infants with hypoxic respiratory failure because of CDH. Two studies report on these infants. 17, 21 No effect of mortality was seen in either study and the typical estimate does not show a reduction in the risk of mortality (typical RR 1.20, 95% CI 0.74, 1.96). A slight increase in the requirement for ECMO was noted in treated infants (typical RR 1.27, 95% CI 1.00, 1.62). Overall, in infants with hypoxic respiratory failure owing to CDH, there was no decrease in the risk of death or in the requirement for ECMO associated with iNO administration (typical RR 1.09, 95% CI 0.95, 1.26).
With the exception of infants with CDH, Finer and Barrington conclude that iNO should be used in term and late preterm infants with hypoxic respiratory failure, who are unresponsive to other therapy. iNO is very effective in reducing the need for extracorporeal membrane oxygenation (with a number needed to treat of five). Starting iNO therapy earlier does not appear to further reduce ECMO requirements or mortality. On the basis of current evidence, Finer and Barrington conclude that it is appropriate to institute iNO in term or late preterm infants when the OI exceeds 25 or when the PaO 2 , while receiving 100% O 2 , is less than 100 mm per Hg. 3 
Inhaled nitric oxide in preterm infants
Respiratory failure in preterm infants can be caused by a variety of conditions, including primary surfactant deficiency (respiratory distress syndrome) or pneumonia. Surfactant therapy has proven to be successful in reducing the risk of pneumothorax and mortality in these infants. 27 However, many preterm infants may have respiratory failure despite surfactant treatment, and the risk of chronic lung injury remains high. Pulmonary hypertension may further complicate the course of these preterm infants with respiratory failure. 28 Treatment options are fewer in this population, as ECMO has an unacceptably high risk of hemorrhagic complications and hyperventilation may further increase the risk of lung damage and chronic lung disease.
Inhaled nitric oxide is an attractive therapeutic agent to consider in the preterm newborn. Elevated pulmonary vascular resistance and pulmonary artery pressure can be shown in premature animals with immature lungs and respiratory distress syndrome. iNO can improve oxygenation in these animal models. 29, 30 Besides the effect on vascular muscle tone, NO plays a role in lung development. 2 However, there is great concern regarding increased coagulopathy associated with exogenous administration of NO, given the risk of intracranial hemorrhage.
Unlike term infants, the potential for the use of iNO in preterm infants involves a broader population. Potential indications could include administration of iNO to prevent hypoxemic respiratory failure, thereby preventing the need for higher ventilator support and possible lung injury. iNO could be used in infants during their acute phase of respiratory distress syndrome if they meet criteria for hypoxic respiratory failure. Finally, infants with evolving chronic lung disease could potentially benefit from iNO. In the review of Barrington and Finer, 4 all three of these groups of infants are evaluated.
For the purposes of the review, Barrington and Finer included all randomized and quasi-randomized clinical trials of preterm infants (<35 weeks gestation) with respiratory failure after adequate treatment with surfactant. Eleven published, randomized, controlled trials of iNO compared with control in preterm infants were identified. 20, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Barrington and Finer separated the trials into studies with entry before 3 days based on oxygenation, 20, 32, 33, [35] [36] [37] 39 studies with entry after 3 days based on risk of bronchopulmonary dysplasia (BPD) 31, 38 and studies of routine use in intubated preterm infants. 34, 40 The results of the analysis are discussed in detail below and in Table 2 .
Trials of iNO in preterm infants eligible within the first 3 days based on oxygenation criteria Seven trials studied ventilated preterm infants with evidence of respiratory failure within the first 3 days of life. 20,32,33,35 -37,39 The mean oxygenation indices of infants enrolled in these 'rescue' studies ranged from 12 to 32. Some of these studies allowed open label treatment with iNO. 20, 36 In the studies with entry before 3 days based on oxygenation, six studies reported on BPD in survivors at 36 weeks postmenstrual age. There was a trend toward a reduction in the risk of BPD in these infants (typical RR 0.89, 95% CI 0.76, 1.05). Seven of these studies reported on mortality before discharge. 20, 32, 35, 36, 39 No statistically significant reduction in 20, 32, [35] [36] [37] 39 showed a slight trend toward a reduction of death or BPD at 36 weeks postmenstrual age (typical RR 0.95, 95% CI 0.88, 1.02).
The incidence of intraventricular hemorrhage (IVH) was reported by five studies. 32, 33, 36, 37, 39 Although no difference was observer in the risk of any IVH (reported by three studies; typical RR 1.00, 95% CI 0.73, 1.37), there was an increase in the risk of severe IVH (grade 3 or 4) in those infants who received iNO (typical RR 1.27, 95% CI 0.99, 1.62), which was of concern. Few of these studies followed up the neurodevelopmental status of infants at 18 to 24 months, so the effect of this finding is uncertain.
Trials of iNO in preterm infants with entry after 3 days based on risk of BPD The two studies that evaluated infants after 3 days of age on the basis of BPD risk are very different both in criteria for enrollment and in the size of the study. The study by Subhedar et al. 31 is relatively small, having enrolled only 25 infants. The study by Ballard et al. 38 is an order of magnitude larger (582 enrolled infants). In the study by Ballard et al., 38 there was a borderline reduction in the risk of BPD at 36 weeks postmenstrual age in survivors (RR 0.88, 95% CI 0.76, 1.02). Owing to the small size of the Subhedar trial, addition of this trail to the meta-analysis has little influence on the typical estimate, which reports a virtually identical risk as the Ballard trial. Mortality before discharge was not improved in infants receiving iNO (typical RR 1.06, 95% CI 0.64, 1.74). When looking at the combined outcome of death or BPD at 36 weeks postmenstrual age, there is a trend toward decreased death or BPD observed in the Ballard study (RR 0.89, 95% CI 0.78, 1.02). Again, the addition of the Subhedar study adds little to the estimate of effect. As these studies occur after the period of highest risk, these trials do not report on IVH. Currently, only a follow-up of the small trial by Subhedar is available. 41 Infants who received iNO in the Subhedar trial had a trend toward less cerebral palsy and developmental delay, although the estimates are broad given the small size of the study.
Trials of the routine use of iNO in intubated preterm infants Two studies report on the routine use of iNO in intubated preterm infants early in life (<3 days of age). Other than being intubated, these studies required no severity of illness for entry. In these studies, the OI was in the 5 to 7 range. Both studies have reasonable sample sizes; Schreiber et al. 34 enrolled 207 infants and Kinsella et al. 40 enrolled 793 infants. No effect is seen in the risk of BPD at 36 weeks postmenstrual age (typical RR 0.96, 95% CI 0.85, 1.08). In the combined outcome of death or BPD at 36 weeks postmenstrual age, the meta-analysis shows a small decrease in the risk of death or BPD at 36 weeks postmenstrual age associated with the routine use of iNO in intubated preterm infants (typical RR 0.91, 95% CI 0.84, 0.99). In the study by Kinsella, 40 there was a trend toward decreased severe IVH (RR 0.77, 95% CI 0.55, 1.09). Both studies report on severe IVH and periventricular leukomalacia. There is a significant decrease in these serious intracranial lesions reported by the typical estimate (typical RR 0.70, 95% CI 0.53. 0.91). To date, only Schreiber 42 followed-up infants. There was a trend toward decreased neurodevelopmental disability in those infants who received iNO (RR 0.53, 95% CI 0.33, 0.87).
Barrington and Finer suggest that, in very sick preterm infants who meet the criteria for poor oxygenation before day 3 of life, rescue therapy with iNO does not improve their survival, survival without BPD or brain injury, even though oxygenation may be improved in the short-term. There is some evidence of an increase in severe IVH and of the combined outcome of severe IVH or periventricular leukomalacia. In view of these findings, iNO should not be routinely used for preterm infants as a rescue therapy in cases of hypoxic respiratory failure. In contrast, the early routine use of iNO in ventilated preterm infants who are not severely ill, but nevertheless are at risk for serious brain injury or BPD, holds some promise. With only a single study reporting on long-term neurodevelopmental outcomes, caution is suggested before more widespread implementation of its use. In view of the lack of a statistically significant benefit and of long-term follow-up from the later use of iNO in infants, who are at risk of BPD, Finer and Barrington do not recommend the use of iNO in this clinical situation.
Conclusions
With the exception of infants with CDH, iNO should be used in term and late preterm infants with hypoxic respiratory failure, who are unresponsive to other therapy. iNO is very effective in reducing the need for extracorporeal membrane oxygenation. The situation regarding the use of iNO in premature infants is less clear. In ventilated preterm infants who show persistent hypoxemic respiratory insufficieny in the first 3 days of life, rescue therapy with iNO does not improve their survival or survival without BPD, even though oxygenation may be improved in the short-term. The early routine use of iNO in ventilated preterm infants who are less severely ill holds some promise. However, caution is advised, given the paucity of data regarding long-term neurodevelopmental outcome. Few benefits have been reported regarding the later use of iNO in infants who are at risk of BPD.
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